Endocrine Pharmacology Practice Questions

Q: Bromocriptine can be used in the following conditions, except:

Diabetes insipidus. **Explanation:** Bromocriptine is a **semisynthetic ergot alkaloid** that acts as a potent **D2 receptor agonist**. Its clinical utility is derived from its ability to mimic dopamine in various pathways. **Why Diabetes Insipidus is the Correct Answer:** Diabetes insipidus (DI) is characterized by a deficiency of Antidiuretic Hormone (ADH) or resistance to it. Bromocriptine has no effect on ADH secretion or the V2 receptors in the kidney. In fact, Bromocriptine is used to treat **Diabetes Mellitus Type 2** (specifically a quick-release formulation approved by the FDA), but it plays no role in the management of Diabetes Insipidus. **Analysis of Other Options:** * **Hyperprolactinoma:** Dopamine is the natural "Prolactin Inhibiting Hormone." By stimulating D2 receptors on pituitary lactotrophs, Bromocriptine effectively suppresses prolactin secretion and shrinks prolactin-secreting tumors. * **Acromegaly:** While dopamine stimulates Growth Hormone (GH) in healthy individuals, it paradoxically **suppresses GH secretion** in patients with acromegaly. Thus, Bromocriptine is used as an adjuvant treatment. * **Parkinsonism:** Parkinson’s disease involves a deficiency of dopamine in the nigrostriatal pathway. As a direct D2 agonist, Bromocriptine helps restore dopaminergic activity and improve motor symptoms. **High-Yield Clinical Pearls for NEET-PG:** 1. **Drug of Choice:** While Bromocriptine is effective, **Cabergoline** is now the preferred drug for hyperprolactinemia due to its higher efficacy, longer half-life (twice-weekly dosing), and better side-effect profile. 2. **Specific Side Effect:** Bromocriptine can cause **digital vasospasm** (Raynaud’s-like phenomenon) and pulmonary/retroperitoneal fibrosis with long-term use. 3. **Postpartum:** It was previously used to suppress postpartum lactation but is now avoided due to risks of seizures and stroke.

Q: Adverse effects of insulin include all of the following except?

Weight loss. The correct answer is Weight loss because insulin is an anabolic hormone [1, 2, 3]. Its primary physiological role is to promote the storage of glucose, lipids, and proteins [1, 2, 3].1. Why Weight Loss is the Correct Answer (The Exception):Insulin does not cause weight loss; rather, weight gain is a classic side effect. Insulin promotes lipogenesis (fat synthesis) and inhibits lipolysis [1]. Additionally, as insulin therapy effectively controls glycemia, it eliminates glucosuria (loss of calories through urine), leading to a net positive energy balance and subsequent weight gain.2. Analysis of Other Options:* Hypoglycemia (Option D): This is the most common and most serious adverse effect of insulin therapy, resulting from an overdose or mismatched carbohydrate intake [1, 2].* Lipodystrophy (Option C): This occurs at the site of injection. It can manifest as Lipoatrophy (immune-mediated loss of fat, rarer with human insulin) or Lipohypertrophy (fat accumulation due to the local anabolic effect of insulin), which can be prevented by rotating injection sites.* Edema (Option A): Known as "Insulin Edema," this occurs due to insulin’s effect on the kidneys, where it promotes sodium and water retention in the distal tubules. It is usually transient and seen during the initiation of intensive therapy.Clinical Pearls for NEET-PG:* Hypokalemia: Insulin shifts potassium into cells (by activating Na+/K+ ATPase) [1, 2]. It is used therapeutically in hyperkalemia but can be an adverse effect during the treatment of DKA.* Somogyi Effect: Post-hypoglycemic hyperglycemia caused by a counter-regulatory hormonal surge.* Local Allergy: Usually a Type I hypersensitivity reaction to contaminants or the insulin molecule itself.

Q: Hypoglycemia is caused by which of the following?

Alcohol intoxication. **Explanation:** **1. Why Alcohol Intoxication is Correct:** Alcohol (Ethanol) metabolism increases the **NADH/NAD+ ratio** in the liver. High levels of NADH shift the equilibrium of pyruvate toward lactate and oxaloacetate toward malate. Since pyruvate and oxaloacetate are essential precursors for **gluconeogenesis**, their depletion inhibits the liver's ability to produce glucose. This is particularly dangerous in fasting states or in individuals with depleted glycogen stores, leading to profound fasting hypoglycemia. **2. Why the Other Options are Incorrect:** * **Thiazides:** These diuretics are known to cause **hyperglycemia**. They inhibit insulin release from pancreatic beta cells (via potassium channel activation) and decrease peripheral glucose utilization. * **Diazoxide:** This is a potassium channel opener used specifically to treat hyperinsulinism. By keeping $K_{ATP}$ channels open, it hyperpolarizes beta cells and **inhibits insulin secretion**, thereby causing hyperglycemia. * **Metoclopramide:** This is a D2 receptor antagonist used as a prokinetic and antiemetic. It has no direct effect on blood glucose levels, though it may affect the timing of glucose absorption by increasing gastric emptying. **3. High-Yield Clinical Pearls for NEET-PG:** * **Disulfiram-like reaction:** Remember the drugs that cause this when taken with alcohol (e.g., Metronidazole, Cefotetan, Sulfonylureas). * **Drug-induced Hypoglycemia:** Other common culprits include Salicylates (in children), Beta-blockers (which also mask hypoglycemic symptoms), and Quinine. * **Drug-induced Hyperglycemia:** Remember the mnemonic **"S-T-E-P-D"**: **S**teroids, **T**hiazides, **E**strogen, **P**henytoin, and **D**iazoxide.

Q: Which antihormone is used in the management of infertility?

Clomifene. **Explanation:** **Clomifene** is the correct answer because it is a **Selective Estrogen Receptor Modulator (SERM)** specifically used as a first-line agent for inducing ovulation in infertility associated with anovulatory cycles (e.g., Polycystic Ovary Syndrome) [2]. **Mechanism of Action:** Clomifene acts as a competitive antagonist at estrogen receptors in the **hypothalamus and anterior pituitary**. By blocking the negative feedback of endogenous estrogens, it triggers an increase in the pulsatile secretion of **GnRH, FSH, and LH**. The rise in FSH stimulates follicular growth, leading to a mid-cycle LH surge and subsequent ovulation [2]. **Analysis of Incorrect Options:** * **Mifepristone (A):** A progesterone receptor antagonist used primarily for medical termination of pregnancy (MTP) and Cushing’s syndrome; it prevents rather than aids conception. * **Danazol (C):** An impeded androgen used in endometriosis and hereditary angioedema. It suppresses the pituitary-ovarian axis, leading to anovulation [1]. * **Finasteride (D):** A 5-alpha-reductase inhibitor used in Benign Prostatic Hyperplasia (BPH) and male pattern baldness; it has no role in female infertility. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** The most common side effect of Clomifene is **multiple pregnancies** (mostly twins) and ovarian hyperstimulation syndrome (OHSS) [2]. * **Contraindication:** It should not be used in patients with ovarian cysts or liver disease [2]. * **Other SERMs:** Remember **Tamoxifen** (used in breast cancer) and **Raloxifene** (used in postmenopausal osteoporosis) [3]. Unlike Clomifene, Raloxifene does not increase the risk of endometrial cancer [4].

Q: Which of the following is a side effect of steroids due to their mineralocorticoid component?

Hypertension. **Explanation:** Glucocorticoids (like Prednisolone or Hydrocortisone) possess varying degrees of cross-reactivity with **mineralocorticoid receptors**. The correct answer is **Hypertension** because it is a direct consequence of this mineralocorticoid activity. 1. **Mechanism of Hypertension:** Mineralocorticoid action (similar to Aldosterone) occurs in the distal convoluted tubules of the kidney. It leads to **Sodium ($Na^+$) and water retention** and **Potassium ($K^+$) excretion**. The resulting expansion of extracellular fluid volume and hypernatremia lead to an increase in blood pressure. 2. **Incorrect Options:** * **Skin striae, Osteoporosis, and Moon face** are all side effects resulting from the **Glucocorticoid component** (metabolic and catabolic effects). * **Skin striae:** Due to protein catabolism and loss of collagen in the dermis. * **Osteoporosis:** Due to decreased osteoblast activity, decreased calcium absorption, and increased PTH sensitivity. * **Moon face:** Due to redistribution of fat (lipogenesis in specific areas). **High-Yield Clinical Pearls for NEET-PG:** * **Dexamethasone and Betamethasone** have the highest glucocorticoid potency but **zero mineralocorticoid activity**, making them safer for patients with heart failure or hypertension. * **Fludrocortisone** is the steroid with the highest mineralocorticoid-to-glucocorticoid ratio, used primarily in Addison’s disease. * **Electrolyte Triad of Mineralocorticoid Excess:** Hypertension, Hypernatremia, and Hypokalemic Metabolic Alkalosis.

Q: Which of the following statements about methimazole and propylthiouracil is incorrect?

Methimazole is more protein-bound than propylthiouracil.. This question tests your knowledge of the pharmacokinetic differences between the two primary Thionamides used in hyperthyroidism. ### **Explanation of the Correct Answer** **Option C is incorrect** because **Propylthiouracil (PTU) is more protein-bound (approx. 60–80%) than Methimazole (virtually 0%).** In pharmacology, protein binding significantly influences a drug's distribution and its ability to cross biological barriers. Because Methimazole has negligible protein binding, it has a larger volume of distribution and crosses the placenta and enters breast milk more readily than PTU. ### **Analysis of Other Options** * **Option A (Correct statement):** Methimazole is secreted into milk in higher concentrations than PTU due to its low protein binding. While both are generally considered safe in low doses during lactation, PTU was historically preferred for this reason. * **Option B (Correct statement):** Methimazole has a **larger volume of distribution (Vd)** because it does not bind to plasma proteins, allowing it to distribute freely into tissues. PTU, being highly protein-bound, remains more confined to the vascular compartment. ### **High-Yield NEET-PG Clinical Pearls** * **Potency:** Methimazole is **10 times more potent** than PTU and has a longer half-life, allowing for once-daily dosing. * **Mechanism:** Both inhibit Thyroid Peroxidase (TPO). However, **PTU uniquely inhibits the peripheral conversion of T4 to T3** (via 5'-deiodinase inhibition), making it the drug of choice in **Thyroid Storm**. * **Teratogenicity:** Methimazole is associated with **Aplasia Cutis** and Choanal atresia; thus, **PTU is preferred in the 1st trimester** of pregnancy. Methimazole is preferred in the 2nd and 3rd trimesters to avoid PTU-induced hepatotoxicity. * **Side Effects:** The most serious side effect for both is **Agranulocytosis** (usually occurs within the first 3 months).

Q: In oral contraceptive pills (OCP), which of the following is used as the estrogen component?

Ethinyl estradiol. **Explanation:** **1. Why Ethinyl Estradiol is Correct:** Ethinyl estradiol (EE) is the most common estrogenic component used in combined oral contraceptive pills (COCPs). Natural estradiol has very low oral bioavailability due to extensive first-pass metabolism in the liver. The addition of an **ethinyl group at the C17 position** makes the molecule resistant to first-pass metabolism, significantly increasing its oral potency and duration of action. Its primary role in OCPs is to inhibit the release of **FSH (Follicle Stimulating Hormone)**, thereby preventing follicular development and providing cycle control. **2. Why Other Options are Incorrect:** * **B. Norethisterone:** This is a first-generation **progestin** (19-nortestosterone derivative), not an estrogen. It acts by thickening cervical mucus and inhibiting LH. * **C. Ethynodiol diacetate:** This is also a **progestin** (prodrug of norethisterone) used in some contraceptive formulations. * **D. Allyloestranol:** This is a synthetic **progestogen** primarily used to prevent threatened or recurrent miscarriage; it is not a standard component of OCPs. **3. High-Yield NEET-PG Pearls:** * **Mestranol:** Another estrogen used in OCPs; it is a prodrug that must be converted to ethinyl estradiol in the liver. * **Mechanism of Action:** Estrogen inhibits FSH (prevents ovulation), while Progestin inhibits LH (prevents LH surge) and renders cervical mucus hostile to sperm. * **Non-contraceptive benefits:** OCPs reduce the risk of **Ovarian and Endometrial cancers**, but may slightly increase the risk of Breast and Cervical cancers. * **Contraindications:** History of thromboembolism, heavy smokers (>35 years), and undiagnosed vaginal bleeding.

Q: Which of the following are the adverse effects of pioglitazone?

All of the above. **Explanation:** Pioglitazone belongs to the **Thiazolidinedione (TZD)** class of antidiabetic drugs. It acts as a selective agonist for the nuclear receptor **PPAR-γ** (peroxisome proliferator-activated receptor gamma), which enhances insulin sensitivity in peripheral tissues. **Analysis of Options:** * **Weight Gain:** This is a classic side effect of TZDs. It occurs due to a combination of fluid retention (edema) and the differentiation of pre-adipocytes into mature adipocytes, leading to increased subcutaneous fat storage. * **Hepatotoxicity:** While the first drug in this class, Troglitazone, was withdrawn due to severe liver failure, Pioglitazone still carries a risk of idiosyncratic hepatotoxicity. Periodic monitoring of liver function tests (LFTs) is clinically recommended. * **Bladder Cancer:** Long-term use (typically >1 year) of Pioglitazone has been linked to an increased risk of urinary bladder cancer. Consequently, it is contraindicated in patients with active bladder cancer or a history of the disease. **Clinical Pearls for NEET-PG:** 1. **Fluid Retention:** TZDs cause sodium and water reabsorption in the collecting ducts. Therefore, they are **contraindicated in NYHA Class III and IV Heart Failure.** 2. **Fracture Risk:** Pioglitazone is associated with decreased bone mineral density and an increased risk of **distal upper and lower limb fractures**, especially in women. 3. **Lipid Profile:** Unlike Rosiglitazone, Pioglitazone has a more favorable effect on lipids, often decreasing triglycerides and increasing HDL. 4. **Mechanism:** Remember "PPAR-γ" for TZDs vs. "PPAR-α" for Fibrates.

Q: Triiodothyronine (T3) as compared to Thyroxine (T4):

Is shorter acting. To understand the differences between **Triiodothyronine (T3)** and **Thyroxine (T4)**, one must look at their binding affinity and metabolic clearance. ### **Explanation of the Correct Answer** **Option B (Is shorter acting) is correct.** T3 has a much lower affinity for plasma proteins (specifically Thyroid Binding Globulin) compared to T4. Because more T3 exists in the "free" active form, it is metabolized and cleared by the body much faster. The half-life of **T3 is approximately 1 day**, whereas the half-life of **T4 is about 7 days**. Consequently, T3 has a shorter duration of action. ### **Why the Other Options are Incorrect** * **A. Is more plasma protein bound:** Incorrect. T4 is 99.9% bound, while T3 is about 99.7% bound. Though the difference seems small, the 10-fold higher concentration of "free" T3 significantly impacts its kinetics. * **C. Is less potent:** Incorrect. T3 is **3 to 5 times more potent** than T4. T3 is the biologically active form that binds to the nuclear thyroid receptor; T4 acts largely as a pro-hormone. * **D. Has delayed action:** Incorrect. Because T3 does not need to be deiodinated (unlike T4) and binds directly to receptors, it has a **rapid onset of action** compared to the lag period seen with T4. ### **NEET-PG High-Yield Pearls** * **Drug of Choice:** Levothyroxine (T4) is the drug of choice for hypothyroidism due to its long half-life (once-daily dosing) and stable blood levels. * **Myxedema Coma:** Liothyronine (T3) is preferred in emergencies due to its rapid onset of action. * **Peripheral Conversion:** T4 is converted to T3 in peripheral tissues by the enzyme **5'-deiodinase**. This conversion is inhibited by **Propylthiouracil (PTU), Propranolol, and Glucocorticoids**—a favorite fact for MCQ examiners. * **Reverse T3 (rT3):** An inactive isomer formed during periods of starvation or severe illness (Euthyroid Sick Syndrome).

Q: Which of the following agents is a dual agonist for both PPAR-α and PPAR-γ receptors?

Beroglitazar. **Explanation:** **Correct Answer: C. Beroglitazar** **Mechanism and Concept:** Beroglitazar belongs to a newer class of drugs known as **Glitazars** (Dual PPAR agonists). These agents act as agonists at both **PPAR-α** (Peroxisome Proliferator-Activated Receptor-alpha) and **PPAR-γ** (gamma) receptors. * **PPAR-α activation:** Leads to a reduction in triglycerides and an increase in HDL (similar to fibrates). * **PPAR-γ activation:** Enhances insulin sensitivity in peripheral tissues (similar to thiazolidinediones). By targeting both receptors, Glitazars aim to treat the "dyslipidemic triad" and insulin resistance simultaneously in patients with Type 2 Diabetes Mellitus. Other examples include Saroglitazar (the first to be approved in India). **Analysis of Incorrect Options:** * **A. Pioglitazone:** This is a pure **PPAR-γ agonist** (Thiazolidinedione). While it has some minor PPAR-α effects compared to Rosiglitazone, it is primarily classified as a PPAR-γ agonist used for insulin sensitization. * **B. Fenofibrate:** This is a fibric acid derivative that acts as a selective **PPAR-α agonist**. Its primary clinical use is the reduction of high triglyceride levels. * **C. Bromocriptine:** This is a **Dopamine (D2) receptor agonist**. A specific quick-release formulation is FDA-approved for Type 2 Diabetes, but its mechanism involves modulating circadian hypothalamic dopamine activity, not PPAR receptors. **High-Yield Clinical Pearls for NEET-PG:** * **Saroglitazar:** The first dual PPAR agonist approved (in India) specifically for diabetic dyslipidemia and Non-Alcoholic Steatohepatitis (NASH). * **PPAR-γ** is associated with side effects like weight gain, edema, and increased risk of bone fractures. * **PPAR-δ (delta):** Some newer experimental agents (Pan-PPAR agonists) target alpha, gamma, and delta receptors.

Question 1

Bromocriptine can be used in the following conditions, except:

Accepted Answer

Diabetes insipidus

Answer

Hyperprolactinoma

Answer

Acromegaly

Answer

Parkinsonism

Question 2

Adverse effects of insulin include all of the following except?

Accepted Answer

Weight loss

Answer

Edema

Answer

Lipodystrophy

Answer

Hypoglycemia

Question 3

Hypoglycemia is caused by which of the following?

Accepted Answer

Alcohol intoxication

Answer

Thiazide

Answer

Diazoxide

Answer

Metoclopramide

Question 4

Which antihormone is used in the management of infertility?

Accepted Answer

Clomifene

Answer

Mifepristone

Answer

Danazol

Answer

Finasteride

Question 5

Which of the following is a side effect of steroids due to their mineralocorticoid component?

Accepted Answer

Hypertension

Answer

Skin striae

Answer

Osteoporosis

Answer

Moon face

Question 6

Which of the following statements about methimazole and propylthiouracil is incorrect?

Accepted Answer

Methimazole is more protein-bound than propylthiouracil.

Answer

Methimazole is secreted into milk.

Answer

Methimazole has a larger volume of distribution than propylthiouracil.

Answer

All of the above are correct differences.

Question 7

In oral contraceptive pills (OCP), which of the following is used as the estrogen component?

Accepted Answer

Ethinyl estradiol

Answer

Norethisterone

Answer

Ethynodiol diacetate

Answer

Allyloestranol

Question 8

Which of the following are the adverse effects of pioglitazone?

Accepted Answer

All of the above

Answer

Weight gain

Answer

Hepatotoxicity

Answer

Increased risk of urinary bladder cancer

Question 9

Triiodothyronine (T3) as compared to Thyroxine (T4):

Accepted Answer

Is shorter acting

Answer

Is more plasma protein bound

Answer

Is less potent

Answer

Has delayed action

Question 10

Which of the following agents is a dual agonist for both PPAR-α and PPAR-γ receptors?

Accepted Answer

Beroglitazar

Answer

Pioglitazone

Answer

Fenofibrate

Answer

Bromocriptine

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?